Zevra Therapeutics, Inc. (Zevra) operates as a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases.
The company is focused on expanding…
Analysis
Middle-of-the-road
Zevra Therapeutics, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group. One caution: reported profits have recently run ahead of actual cash, which we track closely.
The price is attractive. You pay 6.1× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone.
The trajectory is solid and the balance sheet is sturdy. The company scores 18/20 on our value-creation score: strong value creator.
What to watch: Some accounting patterns deserve a closer look. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202320
96
2023202420252026
All-time high
96
Jun 2026
All-time low
18
Jan 2025
Average rank
54
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
58
24
20
16
Price/Earnings
34
12
12
29
Price/Book
51
8
12
50
Dividend Yield
1
1
1
1
Value (overall)
32
12
10
15
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.